Description

• Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Despite the fact that an estimated 50 million people worldwide suffer from diseases affecting the brain and central nervous system, there are no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs, including Alzheimers disease, Parkinsons disease and amyotrophic lateral sclerosis (ALS). The companys approach concentrates on correcting the cellular pathologies driven by misfolded proteins, the altered biology or phenotypes driving these diseases. Yumanity Therapeutics was founded in December 2014 by Susan Lindquist, Ph.D., award-winning protein folding expert, and Tony Coles, M.D., a renowned biotech industry leader. The companys proprietary platforms have already identified one potential new target for treating Parkinsons disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimers disease and ALS. Targeting the underlying protein pathology of neurodegenerative diseases allows the company to discover therapies that may modify the root cause of these rather than only addressing their symptoms. If you are interested in a career at Yumanity Therapeutics, please contact us at careers@yumanity.com.
• 

  Headquarters:40 Guest Street Suite 4410, Boston, Massachusetts, United States

  More
• 

  Phone Number: +1 617-409-5300

• 

  Website: https://www.yumanity.com

• 

  Employees:42

• 

  Revenue:$50 - 100M

• 

  Legal Name:Yumanity Therapeutics

• Yumanity Therapeutics's Social Media

  
• Is this data correct?

• |  NAICS Code: 541714  |

  Show More